
Phil Febbo, MD, chief medical officer, Genomic Health, discusses the impact the Oncotype DX Genetic Prostate Score (GPS) has on patients with clinically low-risk prostate cancer.

Your AI-Trained Oncology Knowledge Connection!


Phil Febbo, MD, chief medical officer, Genomic Health, discusses the impact the Oncotype DX Genetic Prostate Score (GPS) has on patients with clinically low-risk prostate cancer.

Phil Febbo, MD, chief medical officer, Genomic Health, explains the Oncotype DX Genomic Prostate Score (GPS) for patients with clinically low-risk prostate cancer.

Published: March 7th 2017 | Updated:

Published: May 6th 2017 | Updated: